Savolitinib
Title: | A multicenter Phase II study of savolitinib in patients with MET-amplified gastroesophageal junction adenocarcinomas or gastric cancer | |
Lead Author: | ||
Type: | Poster presentation | |
Session Number: | PO.CT02.01 – Phase II Clinical Trials 1 | |
Abstract Link: | https://www.abstractsonline.com/pp8/#!/10828/presentation/10376 | |
Title: | Baseline and on-treatment plasma-based genomics as a predictor of outcome in SAVANNAH: Savolitinib + osimertinib in EGFRm MET overexpressed/amplified NSCLC post-osimertinib | |
Lead Author: | Ryan J Hartmaier, Ph.D, AstraZeneca | |
Type: | Poster presentation | |
Session Number: | LB294/7 | |
Abstract Link: | https://www.abstractsonline.com/pp8/#!/10828/presentation/9996 |
Mesenchymal epithelial transition factor (“MET”) gene amplification is associated with poor prognosis in gastric cancer (“GC”) and gastroesophageal junction adenocarcinomas (“GEJ”). Savolitinib is a potent and highly selective oral MET tyrosine-kinase inhibitor.
Here we reported the preliminary efficacy and safety data from a Phase II trial of savolitinib monotherapy in patients with MET-amplified advanced or metastatic GC/GEJ (NCT04923932). Additionally, utility of plasma-based genomics was investigated in the SAVANNAH Phase II trial of savolitinib in addition to osimertinib in epidermal growth factor receptor (EGFR) mutated, MET overexpressed/amplified non-small cell lung cancer (“NSCLC”) post osimertinib. First presentation of the SAVANNAH results occurred at the
Surufatinib
Title: | Surufatinib plus toripalimab for first-line treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 positive expression: A multicenter, single-arm phase 2 study | |
Lead Author: | ||
Type: | Poster presentation | |
Session Number: | PO.CT02.02 – Phase II Clinical Trials 2 | |
Abstract Link: | https://www.abstractsonline.com/pp8/#!/10828/presentation/10405 |
Surufatinib (a small-molecule inhibitor of vascular endothelial growth factor receptor (“VEGFR”) 1-3, fibroblast growth factor receptor (“FGFR”) 1 and colony-stimulating factor 1 receptor (“CSF-1R”)) plus toripalimab (an anti-programmed cell death protein-1 (“PD-1”) antibody) showed encouraging antitumor activity in solid tumors. Programmed death ligand 1 (“PD-L1”) expression is the established biomarker for first-line immune checkpoint inhibitors therapy in advanced NSCLC. We conducted an open-label, multi-cohort, single-arm Phase II study to evaluate the safety and efficacy of surufatinib plus toripalimab in patients with advanced solid tumors. Here, we reported the results of advanced NSCLC with PD-L1 positive expression cohort (NCT04169672).
HMPL-760
Title: | HMPL-760 is a highly potent and selective reversible BTK inhibitor, targeting BTK and BTKC481S in B-cell malignancies | |
Lead Author: | ||
Type: | Poster presentation | |
Session Number: | PO.ET09.07 – Tyrosine Kinase and Phosphatase Inhibitors 1 | |
Abstract Link: | https://www.abstractsonline.com/pp8/#!/10828/presentation/6728 |
Bruton’s tyrosine kinase (“BTK”), a member of the Tec family, plays a crucial role in signaling through B-cell receptor (“BCR”). BTK inhibition blocks BCR signals and prevents B-cell activation and growth. First-generation BTK inhibitors such as ibrutinib covalently binds to a cysteine residue (“C481”) of BTK. Their most frequent acquired resistance is the development of a serine mutation in the binding site (“C481S”). Next generation BTK inhibitors such as HMPL-760 aim to overcome this resistance to first-generation inhibitors.
The poster outlined preclinical data showing HMPL-760 is a reversible, selective, highly potent BTK inhibitor targeting both BTKWT and BTKC481S. The first-in-human Phase I clinical trials of HMPL-760 are under way in patients with relapsed/refractory B-Cell Non-Hodgkin’s Lymphoma (NCT05190068).
HMPL-306
Title: | Preclinical characteristic of HMPL-306, a CNS-penetrable dual inhibitor of mutant IDH1 and IDH2 | |
Lead Author: | Na Yang, | |
Type: | Poster presentation | |
Session Number: | PO.ET01.01 – Oncogenes and Tumor Suppressor Genes as Targets for Therapy 1 | |
Abstract Link: | https://www.abstractsonline.com/pp8/#!/10828/presentation/8579 |
Mutations in isocitrate dehydrogenase (“IDH”) 1/2 are frequently identified in various cancers, such as acute myeloid leukemia (“AML”), cholangiocarcinoma, chondrosarcoma and glioma. Mutant IDHs (“mIDHs”) cause accumulated 2-hydroxyglutarate, leading to blockage of cell differentiation, thereby inducing malignant transformation. Rare cases were identified carrying co-existing mutations in IDH1 and IDH2. mIDH isoform switching, from mutant IDH1 to mutant IDH2 and vice versa, have been reported as a mechanism of acquired resistance to IDH inhibition in AML and cholangiocarcinoma. Thus, simultaneous inhibition on both mIDH1 and mIDH2 may be a promising strategy to overcome resistance and improve clinical efficacy. HMPL-306, a dual inhibitor of mIDH1/mIDH2, developed by
The poster outlines preclinical data that shows that HMPL-306 is a potent, durable, dual inhibitor of IDH1/2 mutation that crosses the blood brain barrier and demonstrated effect on pharmacodynamic markers that lead to the differentiation of immature malignant cells to mature normal cells. The strong activity and favorable pharmacokinetics profiles support further clinical evaluation.
HMPL-453
Title: | HMPL-453, a highly selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays potent activity in FGFR-altered tumor models | |
Lead Author: | ||
Type: | Poster presentation | |
Session Number: | PO.ET01.07 – Growth Factor Receptors as Therapeutic Targets | |
Abstract Link: | https://www.abstractsonline.com/pp8/#!/10828/presentation/8706 |
Fibroblast growth factors (“FGFs”) and their receptors (“FGFRs”) regulate numerous cellular processes. Dysregulation of FGFR signaling due to receptor fusion, mutation or amplification is observed across multiple cancer types, making activated FGFRs an important therapeutic target. Herein, we presented the preclinical characterization of HMPL-453, a highly potent and selective inhibitor of FGFR1, 2, and 3, discovered and being currently developed in Phase II clinical trial (NCT04353375) by
The presentation outlines preclinical data that shows that HMPL-453 is a highly potent and selective inhibitor of FGFR 1, 2, and 3 with strong activity against FGFR-deregulated tumors in preclinical models, supporting continued investigation in patients with FGFR alterations (such as fusion and mutation) either as a single agent or in combination with PD-1 blockade.
About Savolitinib (ORPATHYS® in
Savolitinib is an oral, potent and highly selective MET tyrosine kinase inhibitor that has demonstrated clinical activity in advanced solid tumors. Іt blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because of mutations (such as exon 14 skipping alterations or other point mutations), gene amplification or protein overexpression.
Іn 2011, AstraZeneca and
About Surufatinib (SULANDA® in
Surufatinib is a novel, oral angio-immuno kinase inhibitor that selectively inhibits the tyrosine kinase activity associated with VEGFR and FGFR, which both inhibit angiogenesis, and CSF-1R, which regulates tumor-associated macrophages, promoting the body’s immune response against tumor cells. Its unique dual mechanism of action may be very suitable for possible combinations with other immunotherapies, where there may be synergistic anti-tumor effects.
About HMPL-760
HMPL-760 is an investigational, non-covalent, third-generation BTK inhibitor. It is a highly potent, selective, and reversible inhibitor against both wild-type and C481S-mutated BTK.
About HMPL-306
HMPL-306 is a novel dual-inhibitor of ꞮDH1 and ꞮDH2 enzymes. ꞮDH1 and ꞮDH2 mutations have been implicated as drivers of certain hematological malignancies, gliomas and solid tumors, particularly among acute myeloid leukemia patients.
About HMPL-453
HMPL-453 is a novel, highly selective and potent inhibitor targeting FGFR 1, 2 and 3. Aberrant FGFR signaling has been found to be a driving force in tumor growth (through tissue growth and repair), promotion of angiogenesis and resistance to anti-tumor therapies. Abnormal FGFR gene alterations are believed to be the drivers of tumor cell proliferation in several solid tumor settings.
About
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the
CONTACTS
Investor Enquiries | |
+852 2121 8200 | |
+1 (973) 306 4490 | |
Media Enquiries | |
+1 (917) 570 7340 (Mobile) bmiles@soleburystrat.com | |
FTI Consulting | +44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile) HUTCHMED@fticonsulting.com |
Brunswick | +852 9783 6894 (Mobile) HUTCHMED@brunswickgroup.com |
Nominated Advisor | |
+44 (20) 7886 2500 | |
Source:
2023 GlobeNewswire, Inc., source